Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of “Buy” by Analysts

Vor Biopharma Inc. (NYSE:VOR) has been assigned an average recommendation of “Buy” from the seven research firms that are presently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have covered the stock in the last year is $11.36.

Several brokerages have issued reports on VOR. JMP Securities reiterated a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a report on Tuesday, December 10th. Robert W. Baird cut their target price on Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. HC Wainwright reissued a “buy” rating and issued a $17.50 price target on shares of Vor Biopharma in a research report on Tuesday, December 10th. Finally, Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Vor Biopharma in a report on Monday, December 9th.

Vor Biopharma Stock Performance

Shares of VOR opened at $1.02 on Tuesday. The firm has a market cap of $70.04 million, a PE ratio of -0.62 and a beta of -0.37. Vor Biopharma has a 52-week low of $0.63 and a 52-week high of $3.14. The business’s 50 day moving average price is $0.81 and its two-hundred day moving average price is $0.92.

Vor Biopharma (NYSE:VOR) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.40) earnings per share for the quarter, meeting the consensus estimate of ($0.40). Research analysts predict that Vor Biopharma will post -1.55 EPS for the current fiscal year.

Institutional Trading of Vor Biopharma

Several institutional investors and hedge funds have recently made changes to their positions in the company. Rosalind Advisors Inc. bought a new stake in Vor Biopharma in the 3rd quarter worth about $54,000. Exchange Traded Concepts LLC grew its holdings in shares of Vor Biopharma by 40.8% in the third quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock valued at $116,000 after acquiring an additional 48,017 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Vor Biopharma during the second quarter valued at approximately $53,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Vor Biopharma during the second quarter worth $63,000. Finally, Hsbc Holdings PLC boosted its position in Vor Biopharma by 177.0% in the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock worth $51,000 after purchasing an additional 31,333 shares during the last quarter. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.